SUBSCRIBE NOW!
Don't Miss Anything We Post. Join Our Email List Today.

First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple cancers



A phase I, first-in-human study reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such as medullary and papillary thyroid, non-small cell lung, colorectal and bile duct cancers, which have been historically difficult to treat.



Source link

Free Mini-Course and Weekly Updates!

Signup now and receive our Awesome Science Mini-Course and weekly updates when we publish new content.

I will never give away, trade or sell your email address. You can unsubscribe at any time.

 

Add a Comment

Your email address will not be published. Required fields are marked *